Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome.

Neoplasma - 1 Jan 2012

Machado-Neto J A, Traina F, De Melo Campos P, Andreoli-Risso M F, Costa F F, Olalla Saad S T

Abstract excerpt

MDM2/p53 pathway plays an important role in the control of apoptotic and proliferation mechanisms, and alterations in this pathway have been described in myelodysplastic syndromes (MDS). We investigated the frequency of MDM2 SNP309, TP53 Arg72Pro polymorphisms in de novo MDS and the association of these polymorphisms with clinical characteristics. Our results showed that the frequencies of genotypes for MDM2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Neoplasm
Share to Myelodysplastic Syndromes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Polymorphism, Restriction Fragment Length

Share to Prognosis

Share to Proto-Oncogene Proteins c-mdm2

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 22668018
DOI: 10.4149/neo_2012_068

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome.PMID 22668018Read ↗

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.Semantic proximity Read ↗

The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.Semantic proximity Read ↗

Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome.Semantic proximity Read ↗

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.Semantic proximity Read ↗

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.Semantic proximity Read ↗

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Semantic proximity Read ↗

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.Semantic proximity Read ↗

MDM2 SNP309 and SNP354 are not associated with lung cancer risk.Semantic proximity Read ↗

Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.Semantic proximity Read ↗

MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.Semantic proximity Read ↗

No association of MDM2 SNP309 with risk of glioblastoma and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.